Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $108.3 million.

  • Apellis Pharmaceuticals' Free Cash Flow rose 21769.12% to $108.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.6 million, marking a year-over-year increase of 13825.2%. This contributed to the annual value of -$88.3 million for FY2024, which is 8517.75% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Free Cash Flow stood at $108.3 million for Q3 2025, which was up 21769.12% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Free Cash Flow ranged from a high of $108.3 million in Q3 2025 and a low of -$177.9 million during Q1 2023
  • Over the past 5 years, Apellis Pharmaceuticals' median Free Cash Flow value was -$112.5 million (recorded in 2021), while the average stood at -$89.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 17964.86% in 2021, then soared by 21769.12% in 2025.
  • Apellis Pharmaceuticals' Free Cash Flow (Quarter) stood at -$112.5 million in 2021, then dropped by 25.84% to -$141.6 million in 2022, then surged by 30.81% to -$98.0 million in 2023, then soared by 119.74% to $19.3 million in 2024, then surged by 460.08% to $108.3 million in 2025.
  • Its Free Cash Flow stands at $108.3 million for Q3 2025, versus $4.4 million for Q2 2025 and -$53.4 million for Q1 2025.